Professional Media briefs: April 2014

Professional Media briefs: April 2014
Professional Media briefs: April 2014

MedCAREERS Group Inc. has launched its free iPhone and iPad Nurses Lounge app, which lets professionals tap into job opportunities, education and career information. The service is like a nurses-only LinkedIn. It started as a direct mail magazine in 2003 and the first lounge—the service has several within nursing—launched in 2009.

Publishing, turned publishing-and-software group F1000, has named Daniel Marovitz its chief executive officer. Marovitz was previously founder and CEO of startup firm buzzumi which is being acquired by F1000. “F1000 is at the center of a disruptive storm in science information that touches… technology and change” Marovitz said in a statement. “It is a tremendous honor to be entrusted with steering this valuable franchise.”

The American Academy of Orthopaedic Surgeons has named Wolters Kluwer Health publisher of its official clinical review journal, which made it part of the Lippincott Williams & Wilkins portfolio as of March. The alliance includes new journal features including pre-print online publication and the ability for authors pay to make their research available to the public for free.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.